Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease.
BACKGROUND
Chronic obstructive pulmonary disease (COPD) is characterized by airway inflammation and is associated with acute exacerbations. Macrolide antibiotics have been shown to exhibit anti-inflammatory effects in some chronic airway inflammatory diseases.


OBJECTIVE
The aim of this study was to assess the effect of treatment with erythromycin on airway inflammation and health outcome in COPD patients.


METHODS
We conducted a randomized, placebo-controlled, double-blind trial of erythromycin for a period of 6 months. Thirty-six COPD patients were randomized to treatment with oral erythromycin (125 mg, three times/day) or placebo. The primary outcomes were neutrophil number in sputum and exacerbations.


RESULTS
Thirty-one patients completed the study. At the end of treatment, neutrophil counts in the sputum were significantly decreased in the group treated with erythromycin compared with placebo-treated patients (p = 0.005). Total cells in the sputum and neutrophil elastase in sputum supernatant were also significantly decreased in those treated with erythromycin compared with the placebo group (p = 0.021 and p = 0.024, respectively). The mean exacerbation rate was lower in the erythromycin group than in the placebo group (relative risk = 0.554, p = 0.042). Kaplan-Meier survival analysis showed that erythromycin significantly delayed the time to the first COPD exacerbation compared with placebo (p = 0.032).


CONCLUSIONS
Erythromycin treatment in COPD patients can reduce airway inflammation and decrease exacerbations and may therefore be useful in the management of COPD.
He
Zhi-Yi
ZY
Respiratory Medicine, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Ou
Li-Mei
LM
Zhang
Jian-Quan
JQ
Bai
Jing
J
Liu
Guang-Nan
GN
Li
Mei-Hua
MH
Deng
Jing-Min
JM
MacNee
William
W
Zhong
Xiao-Ning
XN
D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004917:Erythromycin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D019272:Leukocyte Elastase / Q000032:analysis; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000276:immunology; D011788:Quality of Life; D013183:Sputum / Q000166:cytology / Q000187:drug effects* / Q000276:immunology / Q000382:microbiology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D004917:Erythromycin; D019272:Leukocyte Elastase